1. Home
  2. FRMI vs IMVT Comparison

FRMI vs IMVT Comparison

Compare FRMI & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

FRMI

Fermi Inc.

N/A

Current Price

$7.61

Market Cap

6.0B

Sector

Real Estate

ML Signal

N/A

Logo Immunovant Inc.

IMVT

Immunovant Inc.

HOLD

Current Price

$26.19

Market Cap

5.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FRMI
IMVT
Founded
2025
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.0B
5.3B
IPO Year
2025
N/A

Fundamental Metrics

Financial Performance
Metric
FRMI
IMVT
Price
$7.61
$26.19
Analyst Decision
Strong Buy
Buy
Analyst Count
7
10
Target Price
$30.86
$27.75
AVG Volume (30 Days)
8.2M
1.9M
Earning Date
01-28-2026
02-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.52
$12.72
52 Week High
$36.99
$27.69

Technical Indicators

Market Signals
Indicator
FRMI
IMVT
Relative Strength Index (RSI) N/A 58.44
Support Level N/A $26.35
Resistance Level N/A $27.64
Average True Range (ATR) 0.00 1.39
MACD 0.00 0.06
Stochastic Oscillator 0.00 71.64

Price Performance

Historical Comparison
FRMI
IMVT

About FRMI Fermi Inc.

Fermi Inc is an energy and hyperscaler development company purpose-built for the AI era. Its Project Matador, a multi-gigawatt energy and data center development campus designed to support the accelerating needs of to-be-built AI infrastructure. Through its REIT structure, Fermi offers investors exposure to AI infrastructure growth and long-term, large-scale and reliable energy development in a tax-efficient public vehicle.

About IMVT Immunovant Inc.

Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.

Share on Social Networks: